Dental service organizations, veterinary groups, ambulatory surgery centers, and behavioral health platforms accumulate vendor-contract leakage in patterns specific to clinical operations and post-rollup consolidation. Most of it is invisible to AP teams that were never resourced to enforce contract terms at multi-site scale.
PE-backed healthcare platforms scale through acquisition. Each bolt-on arrives with its own vendor contracts, its own pricing tiers, and its own AP processes. The platform's procurement team — if one exists — is structurally years behind the M&A pace. Negotiated enterprise rates exist on paper while individual locations continue paying legacy prices their controllers never knew were superseded.
Clinical operations layer a second source of leakage. Lab and imaging volumes are billed transactionally, often against rate cards that include hidden surcharges, expedite fees, or tier-step pricing that requires monthly invoice reconciliation to enforce. Medical and dental supply distributors (Henry Schein, Patterson, Benco, Covetrus) operate on rebate programs whose realization rates fall sharply when procurement is not actively reconciling.
Revenue cycle management vendors compound the issue. RCM contracts are typically priced as a percentage of collections, with floor fees, technology surcharges, and statement-cycle pricing that creep upward through the contract term without notice.
Bolt-on locations purchasing supplies (gloves, anesthetics, consumables, dental burs, veterinary pharmaceuticals) at legacy pricing inherited from the pre-acquisition era, while the platform holds enterprise rate cards with Henry Schein, Patterson, Benco Dental, or Covetrus that should apply. Typical realized variance: 8% to 18% against negotiated rates.
IDEXX, Antech, Zoetis, Quest, LabCorp invoicing at per-test rates that do not reflect platform-level volume commitments. Particularly common in veterinary platforms post-rollup. Expedite fees, send-out fees, and pathology surcharges are systematically under-audited.
Revenue cycle vendors (athenahealth, Waystar, R1 RCM, regional billing companies) charging at rates above contract due to undisclosed statement-cycle pricing, technology surcharges, or percentage-of-collections drift. RCM is the highest-LTV reclamation category in PE-backed platforms because the fee base is large and the contract complexity hides the leakage.
CBCT, panoramic, ultrasound, and surgical equipment service contracts auto-renewing at escalated prices, with redundant coverage on equipment that has been retired, sold, or relocated. Post-rollup, multiple service contracts often cover the same physical assets.
Stericycle, Daniels Health, and regional medical waste haulers operate on long-term contracts with annual escalators, fuel surcharges, and environmental compliance fees that compound silently. Multi-site platforms commonly pay 15% to 30% above renegotiated platform rates at locations missed during consolidation.
Practice management licenses (Dentrix, Eaglesoft, Open Dental, Cornerstone, ezyVet, Modernizing Medicine, Cerner) maintained at legacy seat counts and feature tiers post-rollup, even where the platform has standardized on a consolidated stack. Annual escalators in vendor contracts often compound at 5% to 8% above contractual caps.
Ranges drawn from public industry benchmarks (KPMG Supplier Management commentary on up-to-9% contractual leakage; ProcureCon Healthcare; Becker's Dental + Becker's ASC operational benchmark reporting). Specific recovery figures depend on platform scale, rollup history, and procurement maturity.
Illustrative scope and structure. Specific findings vary by platform and are confidential to the engagement.
Findings are delivered as a confidential dossier with line-item evidence, vendor-by-vendor recovery prioritization, and a 90-day implementation roadmap that the sponsor's operating partner can execute against. Where the engagement is sourced through a transaction services or M&A advisory channel, deliverable posture (named, co-branded, or white-labeled) is set at engagement-letter stage.
For PE Operating Partners →Across PE-backed DSO platforms in the US mid-market, forensic vendor audits typically surface recoverable leakage in the 4% to 9% range of audited vendor spend. The upper end is most common in platforms that have completed two or more bolt-on acquisitions without consolidating supply, lab, and imaging vendor contracts.
Reference laboratory pricing. Multi-site veterinary platforms frequently negotiate enterprise rates with IDEXX or Antech at the platform level, but individual practice locations continue paying legacy per-test rates that pre-date the rollup. Reconciliation typically surfaces a 12% to 22% pricing variance against the negotiated rate card.
We maintain a documented client-clearance log refreshed before every engagement. For healthcare platforms, the screen covers competing portfolio companies of the sponsor, treating physicians or veterinarians who hold equity, and any prior engagement with a target's vendors. Conflicts are disclosed at engagement-letter stage and either declined or walled depending on materiality.
Yes. The Vendor Concentration and Leakage Module is structured for 5 to 10 business day delivery against a target's top-200 vendors, designed to slot inside operational due diligence frameworks. For full forensic depth across a 24 to 36 month lookback, plan 4 to 6 weeks running parallel to QofE.
For broader questions about scope, methodology, and engagement structure, see the full Answers page.